John Osborne
Cardiovascular Disease · Grapevine, TXNPI 1114929718
Payments from drug & device makers
Across 1,109 payments — averaging $1198.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$311K
- Amarin Pharma, Inc.$283K
- Boehringer Ingelheim$218K
- Novartis$187K
- Lilly USA, LLC$139K
- Sanofi-aventis U.S. LLC$73K
- plus $118K from 28 others
Across 13 payments — averaging $2191.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- PTC Therapeutics, Inc.$25K
- Cleerly, Inc.$3K
- Novartis$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 187 | $311,282 |
| Amarin Pharma, Inc. | 292 | $283,073 |
| Boehringer Ingelheim | 185 | $218,159 |
| Novartis | 38 | $186,947 |
| Lilly USA, LLC | 146 | $138,791 |
| Sanofi-aventis U.S. LLC | 77 | $72,817 |
| Esperion Therapeutics, Inc. | 68 | $67,794 |
| Cleerly, Inc. | 12 | $13,570 |
| United Imaging Healthcare North America, Inc. | 6 | $11,814 |
| E.r. Squibb & Sons, L.L.C. | 14 | $9,128 |
| Genentech, Inc. | 3 | $7,293 |
| Regeneron Healthcare Solutions, Inc. | 7 | $1,831 |
| AstraZeneca | 8 | $1,352 |
| Siemens Medical Solutions USA, Inc. | 5 | $851 |
| United Imaging Healthcare North America LLC | 4 | $464 |
| Canon Medical Systems USA, Inc. | 1 | $415 |
| Merck | 16 | $381 |
| Itamar Medical Inc | 3 | $335 |
| Regeneron | 5 | $318 |
| Amgen | 3 | $288 |
| Heartflow, Inc. | 4 | $272 |
| Agepha Pharma FZ LLC | 1 | $257 |
| Lexicon Pharmaceuticals, Inc. | 2 | $236 |
| Pfizer | 2 | $230 |
| Johnson & Johnson | 3 | $203 |
| GE HealthCare | 3 | $154 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $130 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $120 |
| Bayer | 2 | $76 |
| Corcept Therapeutics | 1 | $75 |
| Arbor Pharmaceuticals, Inc. | 3 | $73 |
| Alnylam Pharmaceuticals Inc. | 3 | $63 |
| Trevena, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$1,328,823 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Grapevine
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.